Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses areas of concern when approaching the combination and sequencing of liver-directed therapy with systemic therapy.
Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses how the care setting can impact patient outcomes in the treatment of Burkitt lymphoma.
Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the potential sequencing in the combination of liver-directed therapy with systemic therapy.
Bhavesh Shah, RPh, BCOP; and Thomasina Morris, RPh, MHA, BCOP, delve into the challenges faced with using PARP inhibitors as second-line maintenance therapy for the treatment of ovarian cancer.
Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses the results of combining liver-directed therapy with systemic therapy when treating patients with gastrointestinal neuroendocrine tumors.
Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discussed how systemic therapy differs from liver-directed therapy.
Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses the rate of treatment-related mortality and the most common causes in the treatment of Burkitt lymphoma.
Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discussed how liver-directed therapy is approached in the treatment of liver metastases in patients with gastrointestinal neuroendocrine tumors.
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what pharmacists can do to support patients in the intervention or prevention of chronic kidney disease.
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the role of Nrf2 and vitamin K in DNA damage signaling, senescence, and inflammaging.
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the link between senescence and early vascular aging in the context of chronic kidney disease.
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what may be some of the contributing factors to early vascular aging and how might they be counteracted.
Jennifer Andrews, MD, pediatric hematologist-oncologist at Vanderbilt University Medical Center and medical director of Vanderbilt University Medical Center’s blood bank, discusses what health systems can do to address the national blood shortage and increase blood donations.
Jameshia Below, PharmD, an assistant professor of pharmacy practice at the University of Louisiana Monroe College of Pharmacy, explains how palliative care can support the cancer treatment process, and how specialty pharmacies can support this type of care.
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the next steps to identify and develop novel and effective therapeutic targets for vascular calcification and early vascular aging.
Kelan Thomas, PharmD, MS, associate professor of clinical sciences at Touro University California College of Pharmacy, discusses common themes or key points being raised in the field of psychedelic medicine at recent conferences.
Adam Olszewski, MD, associate professor of medicine in Alpert Medical School at Brown University, discusses the factors associated with progression-free survival and overall survival in the treatment of Burkitt lymphoma.
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses the therapeutic strategies or treatments for vascular calcification that have been found to be effective in patients with chronic kidney disease.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses the challenges of treating neuroendocrine tumors in large cancer centers.
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what the current clinical therapeutic strategies and novel treatments are for vascular calcification.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how large cancer centers are able to manage adverse events for individuals with neuroendocrine tumors.
Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses the cardiovascular effects of chronic kidney disease.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses how large cancer centers are able to manage care for individuals with many different physicians.
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses how medial vascular calcification impacts early vascular aging.
Mei Ka Fong, PharmD, BCOP, said oral oncolytics have traditionally always been a major part of the treatment for neuroendocrine tumors.
Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses how pharmacists are limited to traditional treatment of chronic kidney disease, while waiting for new treatment options.
Peter Stenvinkel, MD, PhD, FASN, full professor and senior lecturer at Karolinska University Hospital, Karolinska Institutet, discusses what early vascular aging is, and what its implications are when it occurs in patients with chronic kidney disease.
Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses promising new crystallization treatment of vascular calcification.
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses the importance of pharmacists in helping treat individuals with neuroendocrine tumors.
Clinicians explored at-home monthly injections of somatostatin analogues during the early days of the COVID-19 pandemic in order to keep patients out of health care facilities as much as possible.
